Adeno-associated viral vector 9 (AAV9) has recently been shown to penetrate the blood--brain barrier via intravascular administration, making it a good candidate for diffuse gene delivery. However, the potential side effects of systemic delivery are unknown. Intrathecal viral vector administration may be more invasive than intravenous injections, but it requires far less vector and it can be performed on an outpatient basis, making it an ideal route of delivery for clinical translation. A total of 12 domestic farm pigs (o20 kg) underwent a single-level lumbar laminectomy with intrathecal catheter placement for AAV9 delivery. Animals were perfused and the tissue was harvested 30 days after treatment. Gene expression was assessed by anti-green fluorescent protein immunohistochemistry. Although a single lumbar injection resulted in gene expression limited to the lumbar segment of the spinal cord, three consecutive boluses via a temporary catheter resulted in diffuse transduction of motor neurons (MNs) throughout the cervical, thoracic and lumbar spinal cords. We now present the first successful robust transduction of MNs in the spinal cord of a large animal via intrathecal gene delivery using a self-complementary AAV9. These promising results can be translated to many MN diseases requiring diffuse gene delivery.
INTRODUCTION
Gene delivery to spinal cord motor neurons (MNs) has been a challenge for a long time. 1 Despite multiple demonstrations of robust MN transduction in rodents following adeno-associated viral vector delivery through distinct routes of administration including direct, 2--6 intraneural 7, 8 and intramuscular deliveries, 7, 9 failed attempts to scale-up and reproduce MN transduction in large animals have halted clinical translation of each of these approaches.
Towne et al. 10 demonstrated efficient transduction of nonhuman primate MNs after intramuscular delivery of recombinant AAV vector serotype 6. However, retrograde transport not only relies on a functional axonal retrograde transport, but also it is a segmental therapy with gene expression restricted to the treated level. Moreover, the need of high volumes of vector creates a challenging biomanufacturing dilemma. Using a different approach, our group has demonstrated that direct spinal cord injections can be safely and accurately performed in pigs 11--13 and humans. 14 Nonetheless, the invasiveness of the procedure and limited spread of gene expression are two major disadvantages of this approach.
More recently, means to achieve diffuse gene expression of spinal cord MNs using noninvasive approaches via peripheral administration have become the focus of several research groups. Although efficient gene delivery to dorsal root ganglion neurons can be achieved following delivery of AAV1, 15, 16 AAV6 (ref. 17) and AAV8 (ref. 18) by lumbar puncture, the blood--brain barrier (BBB) has been a limitation for parenchymal transduction of spinal cord neurons after intrathecal injections. On the other hand, several groups have been successful in transducing fetal, neonatal and adult spinal cord MNs via intravenous administration of AAV serotype 9. 19--21 These studies have not only demonstrated the ability of AAV9 to penetrate the BBB, but also its potential for diffuse gene delivery to MNs and, consequently, correction of spinal cord diseases. 22, 23 We have recently demonstrated a successful marriage between AAV9 and intrathecal administration in rodents. 3 We now present the first successful robust transduction of MNs in the spinal cord of a large animal via intrathecal gene delivery of AAV9. These promising results can be translated to many neurological disease processes requiring diffuse gene delivery to MNs such as amyotrophic lateral sclerosis, spinal muscular atrophy and giant axonal neuropathy.
RESULTS

Clinical outcome
Because of the close physiological and morphological resemblance to human spine and spinal cord, pigs are the most reliable species for translational research of neurosurgical approaches to the spinal cord. 24--28 Moreover, they are orders of magnitude closer to humans in size than rodents or even non-human primates. The pig spinal cord averages 45--55 cm compared with 40--60 cm in adult humans (the average length of rhesus and baboon spinal cords are 23 cm and 32.5 cm, respectively 29 ); the spinal cord diameter in pigs averages 0.6--1.1 cm compared with 0.7--1.4 cm in adult humans (the average diameter of rhesus monkey spinal cords does not exceed 0.5--0.6 cm). Nonetheless, different from humans, the pig spinal cord ends within the S2 vertebra and the dural sac ends within S3. For that reason, while intrathecal injections in humans can be performed in the outpatient setting, in pigs a surgical procedure is required for similar administration.
To demonstrate that the surgical procedure for catheter placement was reproducibly safe, we initiated our studies in a small set of animals (n ¼ 3; pilot study) by performing the surgeries and passing the catheters without conducting any vector delivery on day 0. Catheters were anchored to the skin and animals were allowed to recover. On day 1, morbidity was assessed, followed by delivery of vehicle (phosphate-buffered saline containing 5% D-sorbitol) to demonstrate tolerability of the proposed volume of vector to be injected. Finally, on day 2, 1.5 ml of AAV9 (4.28 Â 10E10 vg kg À1 ) was delivered, and catheters were removed. No morbidity was associated with the laminectomy. No catheter shearing or kinking was observed during subdural drain placement. Also, no acute morbidity was associated with vehicle or vector delivery. Finally, neurological evaluation did not reveal any abnormalities.
Once we demonstrated that the surgical procedure was safe, we proceeded with the main study (n ¼ 12). The detailed experimental design is shown in Table 1 . In this study, catheter placement and viral vector delivery happened on the same day. Catheters were not left in place. Once again, no morbidity was associated with the surgical procedure or vector delivery at different volumes or titers.
Transduction pattern of the spinal cord Four weeks after intrathecal injections of AAV9 at different concentrations and different levels of the spinal cord (Table 1) , pigs were euthanized and segments of the spinal cord (three consecutive 2 cm long segments) corresponding to each injected level (cervical, thoracic and lumbar/sacral) were sampled for histological analysis.
Although green fluorescent protein (GFP) expression could not be directly detected under fluorescence immunohistochemistry using an anti-GFP antibody revealed robust and specific gene expression along the pigs' spinal cords. Consistent patterns of transduction were detected in all animals of each individual group, demonstrating that this technique can be highly reproducible.
scAAV9.CBh.GFP (self-complementary (sc) AAV9 with the chicken beta actin short (CBh) promoter and enhanced GFP) penetrated the pia and successfully transduced MNs of the ventral horn, with limited off-target transduction. In all cases, a bilateral transduction pattern was observed. The major difference detected among treatments was the widespread transduction seen throughout the spinal cord of animals that received diffuse delivery, as opposed to Figure 1 . Transduction pattern differences between local vs diffuse spinal cord gene delivery of AAV9. Representative sections of tissue from animals belonging to groups 2 (local delivery, high titer: left column) and 4 (diffuse delivery, high titer: right column). DAB (diaminobenzidine) staining reveals the pattern of GFP expression at each level of the spinal cord. Counter-staining with cresyl violet was performed. Scale bars: 1000 mm; 100 mm (insets). Quantification of gene expression in the spinal cord The percentage of transduced cells and the rostro-caudal spread of gene expression within the sampled segments of the cords were calculated. Cell morphology (cresyl violet staining) and colocalization of transduced cells with acetyl cholinesterasepositive neurons in adjacent slides were used for quantification of GFP-positive cells. The vast majority of MNs in the analyzed lumbar segments of animals belonging to group 4, followed by group 2, were GFP-positive ( Figure 4a ). As expected, gene expression decreased as the distance from the catheter tip increased; this pattern being more evident in the animals that received local delivery of the vector (groups 1 and 2). In these groups, gene expression was mostly concentrated in the lumbar segments of the cord, with o20% of MN transduction in the cervical and thoracic segments. Figure 4 demonstrates that the site of injection (local vs diffuse; groups 1 and 2 vs groups 3 and 4) and the dose (that is, volume and titer differences) have a role in biodistribution. The latter is particularly illustrated in the middle segment of the lumbar cord of group 1 vs group 3.
Detection of GFP in peripheral organs and inflammatory reaction At the time of euthanasia, samples of peripheral organs including heart, spleen, liver, kidneys and ovaries were collected. Purified DNA from these samples was tested by quantitative PCR to determine the copies of GFP vector genomes (vg) per diploid pig genome. In all groups, no GFP vg could be detected 40.01 copies per pig genome in peripheral organs, and in only two cases detected 40.001 vg per pig genome (Table 2) .
AAV gene expression in the central nervous system is considered safe, without associated toxicity and inflammatory reaction. 30--32 However, spinal cords of three (out of twelve) pigs displayed neutrophil clusters surrounding meninges and infiltrated in the parenchyma. As these cases did not correspond to the animals that received high titers of the vector and because immunohistochemistry for GFAP (glial fibrillary acid protein) and Iba-1 did not show reactive astrocytes and microglia in any of the treated animals, we believe that these were the cases of inflammation due to the surgical procedure (that is, iatrogenic meningitis following catheter placement). Importantly, these animals manifested no clinical symptoms of meningitis, including no severe pain or fevers.
DISCUSSION
Our findings support that intrathecal delivery of AAV9 is a very efficient delivery system for diffuse transduction of MNs in the spinal cord. Our study also confirms the scalability of AAV9 with a reporter gene in a large animal, making this vector highly desirable for clinical translation of gene therapy approaches to the central nervous system. AAV delivery to rodents' spinal cord MNs has been exhaustively demonstrated with different serotypes. 5, 7, 8, 19 Viral vector remote delivery to the neonatal spinal cord has also been successfully reported in rodents. 19, 33, 34 However, the limited feasibility of these approaches for human therapy has been a major obstacle for clinical translation. Recently, efficacious transduction of spinal MNs in 3 kg African green monkeys following AAV6 intramuscular delivery, 10 and in neonatal and adult cats after AAV9 intravascular delivery 20 have brought considerable excitement to the field in terms of scalability of these systemic delivery approaches. Nonetheless, while retrograde gene delivery via intramuscular injection requires considerable amounts of vector and functional axonal transport, intravascular delivery may cause widespread offtarget transduction and elicit an immune response. 35 We present, herein, the first validation of intrathecal delivery of AAV9 for diffuse transduction of spinal MNs in an animal with spinal cord size comparable to the adult human being.
Placement of lumbar spinal drains is a standard noninvasive procedure frequently done in humans with relative low morbidity. Lumbar drains are usually placed percutaneously below the level at which the spinal cord ends. Fluoroscopic guidance can be used to reduce the risk of introducing the catheter into the parenchyma and also for confirmation of subarachnoid placement. Equally important, fluoroscopy can help to confirm the level of the catheter tip and ensure that the catheter is not coiling on itself as it is advanced from the lumbar cistern into the cervical region. Rostral placement of these catheters is easier in infants who have a relatively short spinal canal.
We did encounter a gradient effect with respect to volume and titer variations. Our data demonstrate that even with three boluses, the vector does not become equally distributed throughout the cord, and it mostly penetrates in the vicinity of the catheter tip. As drug movement is directly correlated to volume, the smaller the volume, the more limited is the distribution. As cerebrospinal fluid (CSF) is freshly formed each minute, 36 CSF could have been removed and a higher volume of vector per bolus or greater number of boluses could have been injected. Moreover, depending on the location of the puncture, it is possible to target both the brain and the spinal cord. Intrathecal delivery of AAV9 at the level of the cistern magna could certainly result in farther and deeper transduction of the brain to treat brainstem nuclei. One could argue that acute vs chronic delivery and quadruped vs biped locomotion might have a role in biodistribution. While the former is adjustable, the latter is not. In fact, intrathecal delivery of contrast media, anesthetics, chemotherapeutic agents and drugs for dystonia, spasticity or pain are routinely performed in human medicine. 37 In summary, our results will form the basis for optimal design of preclinical toxicology studies depending on the disease process in question.
Gene therapy is one of the most promising approaches for a variety of diseases affecting the spinal cord with nonexistent treatment options such as spinal muscular atrophy, amyotrophic lateral sclerosis, or giant axonal neuropathy. Proof-of-principle studies including gene replacement of defective genes and delivery of neurotrophic factor genes for neuroprotection have demonstrated amelioration of symptoms and increase in survival in relevant rodent models of these MN diseases. 1,9,38--41 Validation of systemic gene delivery in a large animal is the next step and it has been one of the major limitations of gene transfer to the central nervous system. Our study combines desirable features of intrathecal delivery with a viral vector capable of crossing the BBB 42 for widespread gene delivery throughout the spinal cord. The mechanism by which AAV9 transduces spinal cord MNs following systemic delivery has been previously discussed, and it is likely to happen across the BBB in the case of intravascular injections. In our study, the robust transduction seen in dorsal and ventral roots raised the question of whether the vector directly penetrated the root sheaths and then was retrogradely transported through axons to the spinal cord MNs to trigger gene expression. Alternatively, AAV9 might directly penetrate the spinal cord parenchyma, reaching the cell bodies by diffusion. The former mechanism would be expected to affect similar levels of gene expression in both the dorsal root ganglion neurons and spinal MNs, which was not observed. The latter mechanism would be expected to show a gradient of decreasing gene expression in more central cells that reside further from the intrathecal space, which appears to be the case on qualitative evaluation of the distribution of gene expression (Figure 1 ). Thus, our data suggest that AAV9 is not retrogradely transported and it corroborates the studies by Foust et al. 19 and Duque et al. 20 describing inexistent or sparse transduction of MNs following intramuscular delivery of AAV9. Finally, because we did not use mannitol to bypass the BBB, we believe that the current findings support AAV9's ability to penetrate the BBB and pia mater.
AAV9 intrathecal gene therapy for the dorsal root ganglion could be desirable and important for the treatment of neuropathy, pain, or Friedreich's ataxia. While AAV9 may have limited application for the transduction of nociceptive neurons, other groups were successful in demonstrating gene expression in dorsal root ganglion sensory neurons with AAV9 (ref. 43) or other AAV serotypes after intrathecal delivery.
3,17,18,44,45 Moreover, differences in AAV tropism may be advantageous for targeting different disease processes. In conclusion, while our findings have demonstrated clinical relevance of intrathecal AAV9 for disease processes requiring broad transduction of spinal cord MNs, intrathecal delivery of alternative serotypes for transduction of sensory neurons should be similarly validated in large animal models to support translation of other gene therapy approaches to the clinic.
MATERIALS AND METHODS Animals
This study was conducted following a protocol approved by the Emory Institutional Animal Care and Use Committee. Figure 4 . Quantification of MN transduction. Group 1 (local delivery, low titer ¼ black); group 2 (local delivery, high titer ¼ red); group 3 (diffuse delivery, low titer ¼ green); and group 4 (diffuse delivery, high titer ¼ blue). Statistically significant differences between group 4 and the other three groups could be detected at the cervical and thoracic levels. Statistically significant differences due to a titer effect could be particularly detected at the lumbar level (groups 1 and 3 (low titer) vs groups 2 and 4 (high titer)). Statistically significant differences due to a volume effect (that is, 0.5 ml vs 1.5 ml) were clearly detected at the lumbar level (groups 1 vs 3 and groups 2 vs 4). *Po0.001. Reactions were typically done with at least 1000 pig genomic copies, and samples with o0.001 GFP copies per pig genome were considered negative.
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Viral vectors
Recombinant AAV vectors containing the AAV serotype 9 capsid, produced using a triple-transfection method in HEK293 cells, were generated using HEK293 cells grown in serum-free suspension conditions in shaker flasks as described by Grieger and Samulski (unpublished data). In brief, the suspension HEK293 cells were transfected using polyethyleneimine (Polysciences, Inc., Warrington, PA, USA) and the following plasmids (pXX6-80, 46 pGSK2/9 and ptrs-ks-CBh-GFP) to generate scAAV9.CBh.GFP. This vector utilized a cytomegalovirus enhancer, modified chicken beta actin promoter and bovine growth hormone polyadenylation signal. 43 At 48 h post transfection, cell cultures were centrifuged and supernatant was discarded. The cells were resuspended and lysed through sonication as described. 47 550 U of DNase was added to the lysate and incubated at 37 1C for 45 min, followed by centrifugation at 9400 g to pellet the cell debris. The clarified lysate was loaded onto a modified discontinuous iodixanol gradient followed by column chromatography, or purified by a step cesium chloride (CsCl) gradient centrifugation followed by a discontinuous CsCl gradient centrifugation. Animals in the pilot study and in group 3 were injected with the chromatography-purified vector. All other groups used the CsCl-purified vector. Both the purification methods are based on clinical production protocols and provide equivalent high levels of purity and in vivo transduction efficiency. 48 Purified vectors were dialyzed in 1 Â phosphate-buffered saline with 5% D-sorbitol, and titer was obtained by both dot blot 47 and quantitative PCR. 49 
Study design
The study design is summarized in Table 1 . Briefly, 15--20 kg (2.5-monthold) young adult female Yorkshire pigs (Palmetto Research Swine, Reevesville, SC, USA), divided into four groups (n ¼ 3 per group), underwent intrathecal injections of AAV9 at two different titers into the spinal cord. Animals received either a local lumbar 1.5 ml vector injection (groups 1 and 2), or three 0.5 ml boluses at the cervical, thoracic and lumbar regions of the spinal cord (groups 3 and 4). A total of 1.5 ml of scAAV9.CBh.GFP was delivered to all the animals.
Surgical procedures
With the animal in prone position, the surgical field was shaved, washed, draped and prepared in a standard sterile manner. A 5-cm midline incision was then made, followed by a single-level lumbar laminectomy. The dura was incised and an intrathecal catheter (EDM Lumbar Catheter, Medtronic, Inc., Minneapolis, MN, USA) was placed for vector delivery ( Figure 5 ). Animals that received three injections had their catheters initially advanced into the subdural space up to the cervical cord where 0.5 ml of vector was injected. Catheters were then pulled back by 10 cm where 0.5 ml of vector was injected in the thoracic region. Finally, catheters were pulled back by another 10 cm, and 0.5 ml of vector was injected in the lower thoracic/upper lumbar region.
Animals that received a single injection had their catheters advanced up to the lower thoracic/upper lumbar region of the spinal cord, and a total volume of 1.5 ml of vector was injected. After vector infusion, catheters were carefully removed to avoid vector reflux and dura was sutured. Muscle and skin were sutured accordingly.
Euthanasia, perfusion and tissue collection Animals were euthanized 28 days after surgery. Following euthanasia, transcardiac perfusion was performed with heparinized saline solution followed by buffered 4% paraformaldehyde solution using a peristaltic pump (Masterflex Console Drive pump, Cole-Parmer, Vernon Hills, IL, USA). Spinal cord segments corresponding to each injected region of the cord (cervical, thoracic and lumbar) were collected for histological analysis. Samples were calculated based on the position of the catheter tip at the time of injections and the length of spinal cords and catheters. 
DNA analysis in peripheral organs
Quantitative PCR was used to determine viral titer and for the detection of GFP in peripheral organs. Viral and tissue DNA was purified and quantified using SyBR Green as described. 49 All reactions were run at least in duplicate, and the purity of the PCR products was confirmed by a melting curve analysis at the end of the run. Copies of GFP were assessed in each organ sample and normalized to copies of the pig actin locus (with two copies of the genomic reference representing a diploid host genome). Reactions were typically done with at least 1000 pig genomic copies, and samples with o0.001 GFP copies per pig genome were considered negative. The primer sequences for actin were as follows: forward: 5 0 -CTGC GTCTGGACCTGGCTG-3 0 , reverse: 5 0 -ACGCGGCAGTGGCCATCTC-3 0 . GFP primers used here were same as provided in Gray et al. 49 
Histological analysis
Spinal cords were cryosectioned at 40 mm and gene expression was assessed by anti-GFP immunohistochemistry along with diaminobenzidine staining. Hematoxylin and eosin staining, as well as immunohistochemistry with either anti-choline acetyl transferase (ChAT) or anti-glial fibrillary acid protein (GFAP) and Iba-1 antibodies was also performed in adjacent sections to assess for transduction of neuronal cells or glia reactivity, respectively. Finally, diaminobenzidine-stained sections were counterstained with cresyl violet. Images were obtained using a Nikon DS-Fil color digital camera on a Nikon E400 microscope (Nikon Instruments Inc., Melville, NY, USA).
Rabbit anti-GFP (1:500; Invitrogen, Carlsbad, CA, USA), rabbit anti-GFAP (1:5000; DakoCytomation, Glostrup, Denmark), goat anti-ChAT (1:100; Invitrogen) and anti-Iba-1 (1:500; Abcam, Cambridge, MA, USA) primary antibodies were used. Biotinylated secondary antibodies to rabbit or goat were used (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA).
Quantification of gene expression and statistical analysis
Three consecutive segments (2 cm long each) of each level of the spinal cord of all the animals were sectioned at 40 mm and stored, in order to carry out assessment of gene expression. Every 36th section was processed for immunohistochemistry and counter-stained with cresyl violet to reveal GFP expression. Approximately 42 slides per pig were analyzed, and the percent of GFP-positive MNs was averaged for each segment and for each animal. Every 48th adjacent section was processed for immunohistochemistry to reveal choline acetyl transferase-positive neurons and, therefore, confirm the colabeling of GFP-positive MNs. One-way analysis of variance was used to assess for significant differences among groups (Figure 4a ).
